Although there is an abundance of evidence addressing HF, for many important clinical consid- erations, this writing committee was unable to identify suf - cient data to properly inform a recommendation. The writing committee actively worked to reduce the number of LOE C recommendations, especially for Class Irecommended therapies. Despite these limitations, it is apparent that much can be done for HF. Adherence to the clinical practice guidelines herein reproduced should lead to improved patient outcomes. Although of increasing importance, children with HF and adults with congenital heart lesions are not speci cally addressed in this guideline. The reader is referred to publi- cally available resources to address questions in these areas. However, this guideline does address HF with preserved ejection fraction (EF) in more detail and similarly revisits hospitalized HF. Additional areas of renewed interest are stage D HF, palliative care, transition of care, and quality of care for HF. Certain management strategies appropriate for the patient at risk for HF or already affected by HF are also reviewed in numerous relevant clinical practice guidelines and scienti c statements published by the ACCF/AHA Task Force on Practice Guidelines, AHA, ACCF Task Force on Appropriate Use Criteria, European Society of Cardiology, Heart Failure Society of America, and the National Heart, Lung, and Blood Institute. The writing committee saw no need to reiterate the recommendations contained in those guidelines and chose to harmonize recommendations when appropriate and eliminate discrepancies. This is especially the case for device-based therapeutics, where complete align- ment between the HF guideline and the device-based therapy guideline was deemed imperative (5). 